pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·1d ago·1 min read
save

MHRA revises guidance on periodic safety update reports for UK products

Aug 27, 2026·read at raps ↗RegulatoryNeutral

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an update to its pharmacovigilance procedures guidance.

The revision focuses on the preparation and submission of periodic safety update reports (PSURs) for medicines marketed in the United Kingdom.

Companies will need to follow the new advice when compiling safety data, aiming to improve the consistency and timeliness of reporting to the regulator.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Euro Roundup: MHRA updates guidance on submitting safety reports for UK products”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
The Medicines Co2

related stories

  • 1d agoSTAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and moreSTAT
  • Aug 19Enveda’s exercise-simulating obesity tablet clears early clinical testBioSpace
  • Aug 17Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsFierce Biotech
  • Aug 13Opinion: How to disrupt the health misinformation business modelSTAT
  • Aug 12Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesBioPharma Dive